Docking, ADMET Study, Synthesis and Biological Evaluation of Isoxazole Derivatives as Potential Histone Deacetylase Inhibitors
Keywords:
Histone, Anti-cancer, HDAC8, Vorinostat. Molecular Modelling.Abstract
As an epigenetic target, histone acetylation has great therapeutic value. Several disorders, including cancer, are associated with an increase in the activity of histone deacetylase enzymes (HDACs). The hydroxamate group is employed in most HDAC inhibitors, since it is a strong zinc binding molecule (ZBG). Due to their toxicity and poor pharmacokinetic, hydroxamates are not a preferred cancer therapy option. As a result, a possible technique for increasing potency and selectivity is the development of non-hydroximate HDAC inhibitors. By using Glide's Ligand Designer, we were able to create new HDAC inhibitors that had isoxazole moiety as ZBG. Many different aliphatic and aromatic residues were tried to find the best fit for the cap group and the linker. Using authorized Schrodinger modelling software, the potential inhibition over HDAC8 for the best designed items was synthesized and tested. The data demonstrated the effect of different connecting group with isoxazole as zinc binding group. To estimate the pharmacokinetic parameters of the final products, an ADMET/tox study was conducted, the resulting compounds have promising drug-like attributes. Both the intermediate and final chemicals were produced using mild condition procedures and purified using column chromatography. 1R and NMR spectroscopy were used to characterize the chemical structure of the intermediates and the final products. The MTT assay was used to evaluate the inhibition activity against colon cancer cell line (ST-174), which indicated that there is a comparable antiproliferative activity to vorinostat for some of the synthesized compounds.
Downloads
References
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting
epigenetic regulators for cancer therapy:mechanisms and advances
in clinical trials.Signal Transduct Target Ther. 2019 Oct 24;4(1):62.
Jenke R, ReCing N, Hansen FK, Aigner A, Buch T. Anticancer Therapy
with HDAC Inhibitors: Mechanism-Based Combination Strategies
and Future Perspectives. MDPI [Internet]. 2020 Dec 30;13(4):634.
Available from: https://doi.org/10.3390/cancersl3040634
Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation
in human cancer: the potential role of epi-drug in cancer therapy.
Mol Cancer. 2020 Apr 27;19(1):79.
Alwash AH, Alani BG, Ibrahim IT. RECENT PROGRESS IN DEVELOPING
SELECTIVE HISTONE.kerbala.jps. 2021 Apr 24;Pages 28-50.
Al-Amily D, Mohammed MH. Design, Synthesis and Cytotoxicity
Study of Primary Amides as Histone Deacetylase Inhibitors. Iraqi J
Pharm Sci. 2019;Vol.28(2) 2019:151-8.
Al-Hamashi AAAC. Design, Synthesis, and Biological Evaluation of
Novel Histone Deacetylase Inhibitors as Anti-Cancer Agents. 2018.
Al-Hamashi AA, Abdulhadi SL, Ali RMH.
AfterCarfulRevisiontemplateofEgyptian_AH_08282022.pdf. Egyptian
Journal of Chemistry [Internet]. 2022 Aug 27; Available from:
http://ejchem.journals.ekb.eg/
Verna A, Debnath S, Kalle AM. Identification of novel HDAC8 selective
inhibitors through ligand and structure based studies: Exploiting
the acetaterelease channel differences among class I isoforms. Arab
J Chern. 2022;15(6):103863.
Friesner, Murphy RA;, Repasky RB;, Frye MP;, Greenwood LL;, Halgren
JR;, et al. “Extra Precision Glide: Docking and Scoring
Incorporating a Model of Hydrophobic Enclosure for ProteinLigand Complexes,” 2006, 49, 6177-6196. J Med Chern,. 2006;49,
-6196(49, 6177-6196).
RCSB PDB - 1T69: Crystal Structure of human HDAC8 complexed
with SAHA [Internet], [cited 2022 May 13]. Available from:
https://www.rcsb.org/structure/lT69
Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for
liquid simulations] potential functions for proteins, energy
minimizations for crystals of cyclic peptides and crambin. J Am
Chern Soc. 1988;110(6):1657-66.
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT,
et al. Glide:anew approach for rapid, accurate docking and scoring.
Enrichment factors in database screening. J Med Chem.
;47(7):1750-9.
Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, et al.
Structural Snapshots of Human HDAC8 Provide Insights into the
Class I Histone Deacetylases. Structure. 2004;12(7):1325-34.
Sastry GM, Adzhigirey M, Day T, Annabhimoju R,Sherman W. Protein
and ligand preparation: parameters, protocols, and influence on
virtual screening enrichments. J Comput Aid Mol Des.
;27(3):221-34.
Arabia D of C and PET Jubail Industrial College (JIC), PO Box 10099,
Jubail Industrial City 31961, Kingdom of Saudi, Alsawalha M, Bolla
SR, Kandakatla N, Srinivasadesikan V, Veeraraghavan VP, et al.
Molecular docking and ADMET analysis of hydroxamic acids as
HDAC2 inhibitors. Bioinformation. 2019;15(6):380-7.
Judd CS, Morrisett JD, Chari MV, Browning JL. Proton NMR Basics. J
Chem Educ. 1995;72(8):706.
Bartoszewicz A, Kalek M, Nilsson J, Hiresova R, Stawinski J. A New
Reagent System for Efficient Silylation of Alcohols: Silyl ChlorideN -Methylimidazole-Iodine. Synlett. 2008;2008(l):37-40.
Ghosh AK, Shahabi D. synthesis of amide derivative for electron
deficient amines and functionalized carboxylic acid using EDC and
DMAP and acatalyst amout of hobt as coupling reagent.pdf. elesver.
;
Khan AT, Mondal E. A Highly Efficient and Useful Synthetic Protocol
for the Cleavage of tert Butyldimethylsilyl (TBS) Ethers Using a
Catalytic Amount of Acetyl Chloride in Dry Methanol.
Cheminform. 2003;34(31).
Morcillo SP, Cienfuegos LA de, Mota AJ, Justicia J, Robles R. Mild
Method for the Selective Esterification of Carboxylic Acids Based
on the Garegg-Samuelsson Reaction. J Org Chem.
;76(7):2277-81.
Xu ZY, Xu DQ, Liu BY. WILLIAMSON REACTION IN IONIC
LIQUIDS. Org Prep Proced Int. 2004;36(2):156-61.
Meleady P, O’Connor R. Cell Biology (Third Edition). Part Cell Tissue
Cult Assoc Techiniques Sect 1general Techniques Sect 1 Gen
Techniques. 2006;(Cancer Res.l21952):13-20.
Jorgensen WL. The Many Roles of Computation in Drug Discovery.
Science. 2004;303(5665):1813-8.
Kouassil KAR, Ganiyou2 A, BenUl A, Konel MGR, Nobell N
kouakou, Bohoussoul KV, et al. Identification of Potential C-kit
Protein Kinase Inhibitors Associated with Human Liver Cancer:
Atom-based 3D-QSAR Modeling, Pharmacophores-based Virtual
Screening and Molecular Docking Studies [Internet]. 2019 [cited
Aug 22]. Available from:
http://www.sciepub.com/reference/350880
Yadav R, Imran M, Dhamija P, Chaurasia DK, Handu S. Virtual
screening, ADMET prediction and dynamics simulation of
potential compounds targeting the main protease of SARS-CoV-2.
J Biomol Struct Dyn. 2020;39(17):6617-32.
Flipo M, Charton J, Hocine A, Dassonneville S, Deprez B, DeprezPoulain R. Hydroxamates: Relationships between Structure and
Plasma Stability. J Med Chem. 2009;52(21):6790-802.
Mittersteiner M, Voigt MA, Jesus PC de, Brondani PB. Solvent and Catalyst Free Synthesis of Silicon Protected Alcohols. Chem. 2018;3(38):10717-20.
Ghosh AK, Shahabi D. Synthesis of amide derivatives for electron deficient amines and functionalized carboxylic acids using EDC and DMAP and a catalytic amount of HOBt as the coupling reagents. Tetrahedron Lett. 2020; 63:152719.
Dueno EE,Chu F, Kim SI, Jung KW. Cesium promoted O-alkylation of alcohols for the efficient ether synthesis. Tetrahedron Lett. 1999;40(10):1843-6.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
